Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy
| Autor: | Nizar M. Tannir, Cindy Gu, Christopher G. Wood, Surena F. Matin, Eric C. Umbreit, Andrew G. McIntosh, Levi C. Holland, Stephen H. Culp, Jose A. Karam |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Neutrophils medicine.medical_treatment Population Urology Bone Neoplasms Kaplan-Meier Estimate Systemic therapy Nephrectomy Disease-Free Survival 03 medical and health sciences Hemoglobins 0302 clinical medicine Renal cell carcinoma Interquartile range Risk Factors medicine Sunitinib Humans 030212 general & internal medicine Lymphocytes Neoplasm Metastasis education Carcinoma Renal Cell Aged Proportional Hazards Models education.field_of_study business.industry Patient Selection Cancer Cytoreduction Surgical Procedures Middle Aged medicine.disease Confidence interval Treatment Outcome Oncology 030220 oncology & carcinogenesis Female business medicine.drug |
| Zdroj: | CancerReferences. 126(17) |
| ISSN: | 1097-0142 |
| Popis: | BACKGROUND The management of metastatic renal cell carcinoma (mRCC) has evolved rapidly, and results from the Cancer du Rein Metastatique Nephrectomie et Antiangiogeniques (CARMENA) trial bring into question the utility of cytoreductive nephrectomy (CN). The objective of this study was to examine overall survival (OS) and identify risk factors associated with patients less likely to benefit from CN in the targeted therapy era. METHODS Patients with mRCC undergoing CN from 2005 to 2017 were identified. Kaplan-Meier methods and Cox proportional hazards regression analyses were used to assess OS and risk-stratify patients, respectively, on the basis of preoperative clinical and laboratory data. RESULTS Six hundred eight patients were eligible with a median follow-up of 29.4 months. Ninety-five percent of the patients had an Eastern Cooperative Oncology Group performance status less than or equal to 1, and 70% had a single site of metastatic disease. In a multivariable analysis, risk factors significantly associated with decreased OS included systemic symptoms at diagnosis, retroperitoneal and supradiaphragmatic lymphadenopathy, bone metastasis, clinical T4 disease, a hemoglobin level less than the lower limit of normal (LLN), a serum albumin level less than the LLN, a serum lactate dehydrogenase level greater than the upper limit of normal, and a neutrophil/lymphocyte ratio greater than or equal to 4. Patients were stratified into 3 risk groups: low (fewer than 2 risk factors), intermediate (2-3 risk factors), and high (more than 3 risk factors). These groups had median OS of 58.9 months (95% confidence interval [CI], 44.3-66.6 months), 30.6 months (95% CI, 27.0-35.0 months), and 19.2 months (95% CI, 13.9-22.6 months), respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text